Scinai Immunotherapeutics Enhances CDMO Capabilities at BIO-Europe Spring 2026 in Lisbon

Scinai Immunotherapeutics Strengthens Its Position at BIO-Europe Spring

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing therapies for inflammation and immunology, prepares to make a significant impact at BIO-Europe Spring® 2026 in Lisbon, Portugal, from March 23-25. This event symbolizes Scinai's first major international appearance since acquiring Recipharm Israel, an acquisition that significantly bolsters its development and manufacturing capabilities. The company's delegation at the conference includes CEO Amir Reichman, alongside key representatives from its contract development and manufacturing organization, Scinai Biopharma Services Ltd., such as Solomon Gahtan and Dr. Helen Domeshek. Their participation reveals Scinai's strategic intent to engage industry stakeholders and promote its innovative research and development (R&D) as well as its integrated CDMO services.

At BIO-Europe Spring, Scinai seeks to highlight its robust CDMO platform, designed to facilitate client projects across all stages of drug development—from early formulation to commercial production. The company operates with three strategic pillars: a current Good Manufacturing Practice (cGMP) biologics site in Jerusalem, a cGMP small-molecule active pharmaceutical ingredient (API) facility in Yavne inherited from Recipharm, and a collaborative partnership with Recipharm that enhances operational flexibility and technological access. This comprehensive approach not only ensures a seamless transition for clients moving from preclinical trials to commercial production but also significantly reduces associated risks and accelerates developmental timelines.

By showcasing its extensive pipeline of antibody-based immunotherapies targeting autoimmune and inflammatory diseases, particularly those related to dermatology, Scinai aims to assert itself as a leader in the CDMO sector. The company leverages collaborations with renowned institutions, such as the Max Planck Society and the University Medical Center Göttingen, to harness advanced scientific developments. This participation at BIO-Europe Spring is not merely about business networking; it also represents Scinai’s commitment to enhancing its therapeutic offerings and expanding its influence within the biopharmaceutical industry.

In addition to focusing on its manufacturing capabilities, Scinai Immunotherapeutics is fully dedicated to advancing its therapeutic pipelines. The emphasis on antibody-based therapeutics positions the company to address pressing medical needs within the autoimmune disease space, ensuring both innovation and tangible health benefits for patients.

As Scinai Immunotherapeutics steps onto the international stage, the company’s strategic initiatives and collaborations serve as a strong foundation for future growth and recognition in the competitive biopharmaceutical landscape. By participating in high-profile events like BIO-Europe Spring, Scinai not only promotes its operational capabilities but also reinforces its role as a key player in the evolving CDMO ecosystem.